ADCT
NYSE · Biotechnology
Adc Therapeutics Sa
$3.83
+0.05 (+1.32%)
Financial Highlights (FY 2026)
Revenue
79.74M
Net Income
-139,777,433
Gross Margin
92.9%
Profit Margin
-175.3%
Rev Growth
-27.1%
D/E Ratio
3.72
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 92.9% | 92.9% | 56.3% | 56.3% |
| Operating Margin | -149.3% | -134.4% | 17.5% | 15.8% |
| Profit Margin | -175.3% | -166.5% | 14.9% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 79.74M | 109.37M | 66.42M | 54.81M |
| Gross Profit | 74.05M | 101.57M | 37.41M | 30.87M |
| Operating Income | -119,082,803 | -146,995,642 | 11.64M | 8.67M |
| Net Income | -139,777,433 | -172,541,063 | 9.87M | 6.47M |
| Gross Margin | 92.9% | 92.9% | 56.3% | 56.3% |
| Operating Margin | -149.3% | -134.4% | 17.5% | 15.8% |
| Profit Margin | -175.3% | -166.5% | 14.9% | 11.8% |
| Rev Growth | -27.1% | -27.1% | +3.3% | +12.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 187.93M | 187.93M | 206.57M | 213.23M |
| Total Equity | 50.56M | 50.56M | 282.56M | 265.87M |
| D/E Ratio | 3.72 | 3.72 | 0.73 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -95,468,086 | -124,392,650 | 12.50M | 10.42M |
| Free Cash Flow | — | — | 3.90M | 4.50M |